摘要
目的观察阿仑膦酸钠对糖尿病合并原发性骨质疏松症骨密度的影响及其安全性。方法收集在我院就诊的糖尿病合并原发性骨质疏松的门诊及住院患者共106例,所有患者在半年内予口服阿仑膦酸钠连续治疗,测定并比较治疗前后患者骨密度、血钙、血磷和疼痛评分,观察不良反应。结果与治疗前相比,患者治疗后的骨密度值明显升高,疼痛平均积分明显下降(P<0.05)。治疗前后,患者血钙和血磷浓度差异无统计学意义。在治疗过程中,无严重不良反应发生。结论阿仑膦酸钠治疗糖尿病伴骨质疏松症可增加患者骨密度,疗效显著。
Objective To observe the bone density changes after treatment of alendronate sodium for diabetes patients with osteoporosis. Methods A total of 106 diabetes patients with osteoporosis were selected and cured by alendronate sodium for half a year. The changes in bone mineral density, serum calcium, phosphorus, pain scores and adverse reaction before and after treatment were observed and compared. Results Compared with before treatment, bone mineral density was signifi cantly increased with statistical difference and the pain score was greatly decreased（P〈0.05） after treatment. Conclusion Alendronate sodium can increase bone mineral density in the treatment of diabetes patients with osteoporosis.
出处
《世界临床药物》
CAS
2015年第3期182-184,共3页
World Clinical Drug
关键词
阿仑膦酸钠
糖尿病
骨质疏松症
骨密度
alendronate sodium
diabetes
osteoporosis
bone mineral density
